Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is a 300% increase over the number of companies inspected in the previous quarter, when two companies received two inspections.
Most of the companies inspected at the time were involved in the Food and Cosmetics sector. Both the Veterinary and Biologics sectors sectors tied for second most common type.
There were five companies in line with FDA regulations that do not need to adjust their management operations or regulatory/administrative actions. Three should take voluntary action to correct their management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Result |
---|---|---|---|
Darling Ingredients, Inc. | Veterinary | 05/15/2024 | No Action Indicated (NAI) |
Hosoda Bros., Inc. | Food and Cosmetics | 04/01/2024 | Voluntary Action Indicated (VAI) |
Lotus Bakeries North America | Food and Cosmetics | 05/23/2024 | Voluntary Action Indicated (VAI) |
New San Francisco Bait Distributors | Food and Cosmetics | 04/05/2024 | No Action Indicated (NAI) |
San Francisco International Airport | Food and Cosmetics | 04/10/2024 | Voluntary Action Indicated (VAI) |
Signature Flight Support | Food and Cosmetics | 04/10/2024 | No Action Indicated (NAI) |
Southwest Airlines - SFO, Inc. | Food and Cosmetics | 04/11/2024 | No Action Indicated (NAI) |
UCSF Medical Center Clinical Laboratories | Biologics | 05/30/2024 | No Action Indicated (NAI) |